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The Allergen Bureau was established in 2005 and is
funded by membership from the Australian and New
Zealand food industry. The industry developed Guide to
Allergen Management and Labelling is a resource to
ensure consistency in manufacturing practices and label-
ling. VITAL (Voluntary Incidental Trace Allergen Label-
ling) is a risk tool that was developed against a
regulatory background where the labelling of incidental
trace cross contact allergens is not mandated. VITAL is
a risk based methodology to be used in assessing the
impact of allergen cross contact and stipulates a consis-
tent precautionary allergen labelling statement. Applica-
tion of the VITAL system aims to avoid indiscriminate
use of precautionary labelling and contribute to the
minimisation of risk to allergic consumers.
VITAL uses an action level grid to assist in determining
if the presence of residual protein from allergenic sub-
stances through cross contact requires precautionary
labelling. VITAL is based on the premise that some pro-
ducts may have foreseeable levels of an allergen present
through incidental cross contact, and this will not be
labelled where the level is below a specified action level.
Due to the wide use and international interest in VITAL,
it is important that VITAL be reviewed regularly to
ensure that it can be considered to be the best available
tool for cross contact allergen risk management.
The purpose of this presentation is to provide infor-
mation on the status of VITAL today and to outline the
review process currently underway .A significant ele-
ment in this process is the establishment of a scientific
expert panel to review current clinical data, population
data, and to consider the application of probabilistic
modelling to the current action levels. This expert panel
will meet in Australia in January 2011 and we hope to
be able to report on the outcomes of the first meeting
and the next steps in the journey .A consistent approach
to cross contact risk assessment is key to ensuring relia-
bility of labelling and consumer confidence and safety.
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